Japanese Pharmacopoeia(JP) - Present and Future -

#### Mayumi SHIKANO, Ph.D. Associate Center Director (for Advanced Review with Electronic Data Promotion and Science Board) Pharmaceuticals and Medical Devices Agency (PMDA)



Pharmaceuticals and Medical Devices Agency (PMDA

- 1. What's JP?
  - History & Legal Status
  - Roles & Characteristics
- 2. How to establish JP ?
  - Main Policy & System
  - Introduction of JP16 & its Supplements
- 3. JP's perspective for the future



## 1. What's JP?

- History & Legal Status
- Roles & Characteristics

## 2. How to establish JP?

- Main Policy & System
- Introduction of JP16 & its Supplements

## 3. JP's perspective for the future



## History and Legal Status of JP

 JP was first published on June 25, 1886 and implemented on July 1, 1887

 $\rightarrow$  JP has the history of 128 years

- JP is published by the Japanese Government as a Ministerial Notification by the Ministry of Health, Labour and Welfare
- JP is published in accordance with the Pharmaceutical Affairs Act (PAA) which is the most fundamental law for pharmaceutical regulation in Japan.



To show standards for quality of drugs

## Official

 To be used extensively by the persons concerned

## Public

To be transparent/disclosed information in the process of establishment



## History of JP Edition -Number of Monographs on Drugs-

Edition	Date of publication	Number of monographs
JP 1	1886. 6. 25	468
Ļ	$\downarrow$	$\downarrow$
JP 16	2011. 3. 31	1764
Suppl. I	2012. 9. 27	1837
Partial rev.	2013. 5. 31	1837
Suppl. II	2014. 2. 28	1896
Ļ	$\downarrow$	$\downarrow$
JP 17	2016 Spring	•••

In recent years, the new editions are published every 5 years and two supplements are published between the regular publication of JP editions.

Moreover, partial revisions are made as necessary.



## **Composition of the JP16**

#### JP 16th Edition comprises the following items,

- Notification of MHLW
- Contents

Preface

**General Notices** 

General Rules for Crude Drugs

**General Rules for Preparations** 

**General Tests** 

**Official Monographs** 

Ultraviolet-visible Reference Spectra

Infrared Reference Spectra


**General Information** 

Table of Atomic Mass as an appendix



**Mandatory Part** 

# JP English version - JP16 and its Supplements -



JP	Japanese	English
JP16	Mar 2011	Feb 2012
JP16 Suppl. I	Sep 2012	Apr 2013
JP16 Suppl. II	Feb 2014	Aug 2014

 JP English electric version can be downloaded <u>freely</u> from the JP English website; <u>http://www.pmda.go.jp/english/pharmacopoeia/index.html</u>



#### 1. What's JP?


- History & Legal Status
- Roles & Characteristics

## 2. How to establish JP?

- Main Policy & System
- Introduction of JP16 & its Supplements

## 3. JP's perspective for the future





JP 17<sup>th</sup> Edition (JP17)

To be published in 2016 spring




## **Basic Principles for Preparation of JP17**


Published in September 2011

- 1. Include all drugs which are important for health care and medical treatment
- 2. Make qualitative improvement by introducing the latest science and technology
- 3. Promote internationalization
- 4. Make prompt partial revision as necessary and facilitate smooth administrative operation
- 5. Ensure transparency regarding the revision, and disseminate the JP to the public



## Secure System for Establishing JP







Pharmaceuticals and Medical Devices Agency (PMD

### 1. What's JP?

- History & Legal Status
- Roles & Characteristics

## 2. How to establish JP?

- Main Policy & System
- Introduction of JP16 & its Supplements

## 3. JP's perspective for the future



## Priorities to be addressed

- Internationalization of pharmacopoeia
  - Prompt publication of the JP English Edition
  - Further improvement on the JP English Website
  - Promotion of the PDG activities and practical use of PDG harmonized texts worldwide
  - Buildup of the frameworks for international information
     exchange among pharmacopoeias

e.g. Cooperation with the International Meeting of World Pharmacopoeias (WHO)

 Enhance cooperative relationships with each pharmacopoeia including Brazilian Pharmacopoeia, USP, EP and WHO.
 e.g. Workshop for training, Exchange of experts




## **Expectations for Brazilian Pharmacopoeia**

PMDA(JP) would like to express sincere respect for your efforts in realization of MERCOSUR Pharmacopoeia and Good Pharmacopoeial Practices.

PMDA(JP) would like to promote cooperation with Brazilian Pharmacopoeia by sharing experience in international harmonization of pharmaceutical regulations through ICH and PDG, etc.





#### Japanese Pharmacopoeia Top Page



## Thank you for your attention ! Obrigada!!



Please visit to our website: http://www.pmda.go.jp/english/pharmacopoeia/index.html

E-mail: shikano-mayumi@pmda.go.jp

